In line with this, in a preclinical study, MYCi975 inhibitor, suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1, and finally sensitized tumors to anti-PD1 immunotherapy [59]. The gene discussed is PDCD1; the disease is neoplasm.